IP Library › Granted Patent US 11,739,140
Granted Patent B2
US 11,739,140 · App. 17/144,355 · Granted Aug 29, 2023

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Inventors: Jan Torleif Pedersen (Valby, DK); Lars Østergaard Pedersen (Valby, DK); Justus Claus Alfred Daechsel (Valby, DK); Ayodeji Abdur-rasheed Asuni (Valby, DK); Nina Helen Rosenqvist (Valby, DK); Christiane Volbracht (Valby, DK); Lone Helboe (Valby, DK); Anders Brandt Elvang (Valby, DK); Florence Sotty (Valby, DK); Søren Christensen (Valby, DK); Jeffrey B. Stavenhagen (Valby, DK)
Assignee: H. Lundbeck A/S
C07K16/18A61K39/395A61K49/00G01N33/6896A61K2039/505C07K2317/24C07K2317/30C07K2317/33C07K2317/34C07K2317/565C07K2317/76C07K2317/92C07K2317/94G01N2333/4709G01N2800/2821
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,739,140
App. No.
17/144,355
Granted
Aug 29, 2023
Kind
B2
Abstract

The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

Claims (18)

1. An immunoglobulin molecule comprising:

(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:1;

(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:2;

(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:3;

(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:4;

(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and

(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:6.

2. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is a monoclonal antibody or a bispecific antibody having an Fc domain.

3. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is an epitope-binding fragment of a monoclonal antibody that is selected from the group consisting of: an Fv fragment, an Fv fragment fused to an Fc domain, a Fab fragment, a Fab′ fragment, a F(ab)2 fragment, a single VH variable domain and a single VL variable domain.

4. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is a humanized antibody.

5. The immunoglobulin molecule according to claim 1 , comprising the heavy chain of SEQ ID NO:8 and/or the light chain of SEQ ID NO:7.

6. The immunoglobulin molecule according to claim 1 , comprising the heavy chain of SEQ ID NO:8 and/or the light chain of SEQ ID NO:34.

7. A pharmaceutical composition comprising immunoglobulin molecule according to claim 1 , and a pharmaceutical acceptable carrier.

8. A nucleic acid encoding the immunoglobulin molecule according to claim 1 .

9. A method of treating Alzheimer's disease or other tauopathy in a subject in need thereof, said method comprising administering to said subject an effective amount of the immunoglobulin molecule of claim 1 .

10. A method of diagnosing or imaging Alzheimer's disease or other tauopathy in a subject in need thereof, wherein said method comprises administering to said subject an amount of the immunoglobulin molecule of claim 1 sufficient to detect or measure the presence or amount of a hyperphosphorylated variant of human tau in the brain of a said subject.

11. A method of treating Alzheimer's Disease in a subject in need thereof, wherein said method comprises administering to said subject an amount of the immunoglobulin molecule of claim 1 sufficient to reduce or attenuate the accumulation of pathological tau protein in said patient.

12. The immunoglobulin molecule of claim 1 , wherein the immunoglobulin molecule is capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:33).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2021
From: PEDERSEN, JAN TORLEIF; PEDERSEN, LARS OSTERGAARD; DACHSEL, JUSTUS CLAUS ALFRED; ASUNI, AYODEJI ABDUR-RASHEED; ROSENQVIST, NINA HELEN
To: H. LUNDBECK A/S
Reel/Frame 054901/0840 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2021
From: VOLBRACHT, CHRISTIAN; HELBOE, LONE; ELVANG, ANDERS BRANDT; SOTTY, FLORENCE; CHRISTENSEN, SOREN; STAVENHAGEN, JEFFREY B.
To: H. LUNDBECK A/S
Reel/Frame 054902/0084 →
Priority Claims (2)
GB 1512211 · Jul 13, 2015 · national
GB 1518375 · Oct 16, 2015 · national
Continuity (4)
Continuation 16723143 · Dec 20, 2019
Continuation 16188489 · Nov 13, 2018
Continuation 15207836 · Jul 12, 2016
Related Publication 20210206843A1 · Jul 8, 2021